AZN AstraZeneca PLC

Hardman & Co Research: AstraZeneca: Where has all the cash gone?

Hardman & Co Research
Hardman & Co Research: AstraZeneca: Where has all the cash gone?

05-Jun-2019 / 12:36 GMT/BST


Hardman & Co Research: AstraZeneca: Where has all the cash gone?

Historically, AstraZeneca (AZN) was a leading global pharmaceutical company, but it has slipped down the rankings following a period of patent expiry on major drugs, notably Nexium, Losec and Seroquel. Understandably, the financial performance, particularly operational cashflow, has suffered through this period and AZN has moved from a net cash ($339m) position in 2009 to net debt of $16.3bn at the end of 1Q'19, necessitating a cash call. Better planning, notably earlier cessation of share buybacks and re-basing its dividend, would have left it in a much stronger position. Meanwhile, its use of 'core' EPS greatly overstates true performance.

Please click here for the full report:

To contact us:

Hardman & Co
35 New Broad Street
London
EC2M 1NH

Follow us on Twitter @HardmanandCo
Contacts:

Dr Martin Hall
Dr Dorothea Hill
Dr Gregoire Pave

2




 

Hardman & Co Research can still be accessed for free after MiFID II. Please to read the statement.

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

819819  05-Jun-2019 

fncls.ssp?fn=show_t_gif&application_id=819819&application_name=news&site_id=research_pool
EN
05/06/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AstraZeneca PLC

AstraZeneca PLC - December 2023 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

AstraZeneca PLC: Update to credit opinion

Our credit view of this issuer reflects its broad product portfolio, constrained by its degree of uncertainty related to patent challenges.

Baptiste Salaville ... (+4)
  • Baptiste Salaville
  • Florent Laroche-Joubert
  • Jean-Baptiste Rouphael
  • Stefano Toffano

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 13/03/2024

L’année 2024 sera marquée par l’élection présidentielle américaine et l’annonce des rabais pour les 10 médicaments dont les prix sont dorénavant négociés directement par Medicare dans le cadre de l’IRA. Nous tablons sur une croissance des BPA 24e de 8% et relevons nos OC de 1% en moyenne. Nous privilégions GSK (Surperformance) qui allie valorisation attractive, croissance et newsflow. Nous maintenons notre recommandation Surperformance sur Sanofi qui devrait bénéficier d’un catalyseur...

Baptiste Salaville ... (+4)
  • Baptiste Salaville
  • Florent Laroche-Joubert
  • Jean-Baptiste Rouphael
  • Stefano Toffano

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 03/13/2024

2024 is set to be marked by the US presidential election and the announcement of rebates for the 10 drugs for which prices are now negotiated directly through Medicare under the IRA. We forecast EPS 24e growth of 8% and lift our target prices by 1% on average. We prefer GSK (Outperform) which combines an attractive valuation, growth and clinical newsflow. We maintain our Outperform rating on Sanofi which should benefit from a transformative clinical catalyst in H1. We lower our rating...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch